Navigation Links
Pharmasset to Present at Deutsche Bank Healthcare Conference
Date:5/14/2009

condarily, on the development of Racivir(R) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleos(t)ide analogs, a class of compounds which act to inhibit the enzymes required for viral replication. We currently have three clinical-stage product candidates: R7128, a nucleoside analog for chronic HCV infections, has initiated a Phase 2b clinical trial in combination with Pegasys plus Copegus through a strategic collaboration with Roche; PSI-7851, an unpartnered, next generation HCV nucleotide analog, which recently began Phase 1 clinical studies and Racivir, for the treatment of HIV that has completed a Phase 2 clinical trial.

        Pegasys(R) and Copegus(R) are registered trademarks of Roche.

        Contact
        Richard E. T. Smith, Ph.D.
        VP, Investor Relations and Corporate Communications
        richard.smith@pharmasset.com
        Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause ou
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Pharmasset to Present at Two Upcoming Investor Conferences
2. Pharmasset to Present at Two Upcoming Investor Conferences
3. Pharmasset to Present at the 27th Annual JPMorgan Healthcare Conference
4. Pharmasset to Webcast an Investor Event from the AASLD Meeting
5. Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
6. Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
7. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
8. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
9. Pharmassets Underwriters Release Shares from Lock-Up
10. Medco to Present at the Deutsche Bank 34th Annual Health Care Conference
11. Perforomist Inhalation Solution data to be presented at American Thoracic Society conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... August 01, 2015 , ... Super Bowl 50 will emanate from Levi’s Stadium ... day each year is the Super Bowl. In the two weeks that separate the conference ... host venue. The 2016 Super Bowl game will mark the 50th time it has been ...
(Date:7/31/2015)... VA (PRWEB) , ... July 31, 2015 , ... ... introduced its new store run by GoodThreads. The store can be accessed by ... and designs, many of which are customizable. The best part: whenever a product ...
(Date:7/31/2015)... ... July 31, 2015 , ... Jacksonville-based drug and alcohol rehabilitation ... Conference Center. The medical community, social workers, law enforcement, and government officials are ... in the effort to better understand and combat sex trafficking. Lead by sex ...
(Date:7/31/2015)... York, NY (PRWEB) , ... July 31, 2015 , ... ... Rodgers Theatre . Those looking to catch a new and refreshing show on ... won numerous awards and achievements including an Obie Award, Outer Critics Circle Award, Drama ...
(Date:7/31/2015)... York (PRWEB) , ... July ... ... attorney Jason T. Brown’s live lecture on pharmaceutical negligence is now available ... 2015 was well received with a 94% approval rating from the nationwide ...
Breaking Medicine News(10 mins):Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 4Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 5Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 6Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 7Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2
... , PRINCETON, N.J., Sept. 9 NephroGenex, Inc., ... announced the completion of patient enrollment in its Phase 2b clinical ... candidate Pyridorin(TM) (pyridoxamine dihydrochloride ) in type 2 diabetic patients ... have been randomized. , , The ...
... , , , ... -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX ) ... Caldolor((R)), an intravenous formulation of ibuprofen, designed primarily for use in ... available in the United States for the treatment of pain and ...
... ... provide comprehensive security solution which includes PHARMORX,s new iPhone application for authentication and ... and diversion of products, within the pharmaceutical, food and beverage, cosmetic and consumer ... ...
... , , , ... 9 Research shows that 80 percent of cardiac events in women could ... exercise and abstinence from smoking. That,s why the American Heart Association,s Go Red ... yet life-saving - choices for their hearts in a new 30-minute NBC television ...
... PRINCETON, N.J., Sept. 9 Covance Inc. (NYSE: ... Weisel Partners 2009 Healthcare Conference on Thursday, September 10, 2009 at ... the presentation at www.covance.com . In order ... minutes early. , , Covance, with headquarters in ...
... , MURRIETA, Calif., Sept. 9 ... division provides drug and alcohol rehabilitation and a variety of ... announced today that Jerrod Menz, Forterus Vice President and co-founder ... Fent, Executive Vice President, will be interviewed on the VoiceAmerica ...
Cached Medicine News:Health News:NephroGenex Announces Full Enrollment in New Pyridorin(TM) Clinical Trial - PYR 210 2Health News:Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever 2Health News:Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever 3Health News:Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever 4Health News:Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever 5Health News:Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever 6Health News:Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever 7Health News:Providers of Packaging Design, Security Printing, and Track and Trace Technology Allign to Provide Multi-Layered Brand Protection Solution 2Health News:Providers of Packaging Design, Security Printing, and Track and Trace Technology Allign to Provide Multi-Layered Brand Protection Solution 3Health News:Providers of Packaging Design, Security Printing, and Track and Trace Technology Allign to Provide Multi-Layered Brand Protection Solution 4Health News:Providers of Packaging Design, Security Printing, and Track and Trace Technology Allign to Provide Multi-Layered Brand Protection Solution 5Health News:Go Red For Women and NBC Team Up to Help Women 'Choose to Live' 2Health News:Go Red For Women and NBC Team Up to Help Women 'Choose to Live' 3Health News:Go Red For Women and NBC Team Up to Help Women 'Choose to Live' 4Health News:Go Red For Women and NBC Team Up to Help Women 'Choose to Live' 5Health News:Forterus Inc. Executives to Be Interviewed on VoiceAmerica 2
(Date:7/31/2015)... July 31, 2015 According to ... by Product (Bioimpedance Analyzers (BIA), Dual-Energy X-ray Absorptiometry (DEXA), ... - Global Analysis & Forecast to 2019", published by ... at $911.1 Million 2014 and is estimated to grow ... of 9.4% from 2014 to 2019. ...
(Date:7/30/2015)... Mettler-Toledo International Inc. (NYSE: MTD ) today announced ... highlights: , Sales in local currency increased ... Reported sales decreased 4% as currency reduced sales growth ... per diluted share as reported (EPS) were $2.73, compared ... $2.80 , an increase of 9% over the ...
(Date:7/30/2015)... SAN DIEGO, July 30, 2015  ResMed Inc. (NYSE: ... ended June 30, 2015.  Revenue for the quarter was ... quarter ended June 30, 2014 (a 17 percent increase ... million, consistent with the quarter ended June 30, 2014. ... consistent with the quarter ended June 30, 2014.  ...
Breaking Medicine Technology:Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
... the Phase III ZODIAC study in advanced non-small cell ... presented today at the American Society of Clinical Oncology ... met its primary endpoint, demonstrating that the addition of ... in progression-free survival (PFS), the length of time a ...
... at 45th American Society of Clinical Oncology Annual ... today announced results from Phase I and II ... inhibitor currently being studied in multiple tumor types. ... Annual Meeting of the American Society of Clinical ...
Cached Medicine Technology:Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology 2Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology 3Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology 4Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology 5Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506 2Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506 3
... YAG III is the new disruption ... in particular for applications in posterior ... the YAG laser is also used ... IOL polishing. It's another milestone in ...
... The Afinion HbA1c test and ... give you reliable facts conveniently ... need them. Advising the patient ... confidence. The HbA1c Test Cartridge ...
An aid for advancing a pacemaker lead through the subcutaneous tissue of the chest wall to the pacemaker pocket....
The Vivid e delivers everything you need in a compact echo system, like complete cardiovascular functionality, a comprehensive cardiac measurement and analysis package, and full shared service capabi...
Medicine Products: